SAFC Expands Irvine Facility to Add Dry Powder Media Manufacturing Capabilities

      SAFC Expands Irvine Facility to Add Dry Powder Media Manufacturing

PR Newswire

ST. LOUIS, March 5, 2013

ST. LOUIS, March 5, 2013 /PRNewswire/ --Sigma-Aldrich^® Corporation (NASDAQ:
SIAL) today announced that SAFC^® (, its custom
manufacturing and services business unit, will expand its manufacturing plant
in Irvine, Scotland to include large-scale production of bulk dry power media
and reagents. Designed to support the expanding needs of the European and Asia
Pacific market, SAFC's Irvine facility expansion will result in redundant
manufacturing capabilities in conjunction with SAFC's existing dry powder
media facility in Lenexa, KS.

The addition of the dry powder milling and blending capability to the Irvine
facility will complete the 5-year Capital Expansion Plan SAFC initiated as
part of its long-term commitment to supporting customers in the growing
industrial biopharmaceutical market. SAFC will construct a purpose-built
Animal Component Free (ACF) dry powder media manufacturing facility to
complement the existing liquid cell culture media, buffers, and reagents
capabilities in Irvine. Ground breaking for the new facility is expected to
commence in March 2013 and should be manufacturing-ready in Q1 of 2014. Once
complete, the facility will be one of the most modern and fit-for-purpose
media facilities in the industry.

"Accelerated development schedules have proven to be a critical component of
success for our customers. They need a guarantee that the suppliers they work
with are in a position to respond rapidly to their unique project
requirements," stated Rod Kelley, SAFC Vice President of Manufacturing. "We've
applied our know-how and experience, best practices, and current technology to
the facility design and approach with the goal to deliver a high-quality
product in a manner that supports the efforts of our customers."

The facility expansion will also include additional raw material and finished
goods warehousing as part of the new manufacturing capability. As with the
current Irvine manufacturing and warehouse facilities, the new expansion will
also be fully compliant with appropriate US FDA and EU cGMP requirements and
comply with local requirements with regard to safety and environmental

"We remain committed to investing in areas where we can deliver tangible value
for our global customer base," stated Gilles Cottier, President of SAFC.
"These investments and subsequent customer benefits continue to set SAFC apart
as a supplier of choice in the industry. We are grateful to Scotland's First
Minister, Alex Salmond, and Scottish Enterprise for their support with this
expansion in Scotland."

To learn more about SAFC's investment in Scotland, please click here.
To learn more about SAFC's dry powder capabilities, please click here.

The foregoing release contains forward-looking statements that can be
identified by terminology such as "will result," "should" or similar
expressions, or by expressed or implied discussions regarding potential future
revenues from products derived there from. You should not place undue reliance
on these statements. There can be no guarantee that the products in SAFC's
service offering will continue to meet the demands of the marketplace. Nor can
there be any guarantee that any of these products will achieve any particular
levels of revenue in the future. Such forward-looking statements reflect the
current views of management regarding future events, and involve known and
unknown risks, uncertainties and other factors that may cause actual results
to be materially different from any future results, performance or
achievements expressed or implied by such statements. In particular,
management's expectations regarding these products could be affected by, among
other things, unexpected regulatory actions or delays or government regulation
generally; the Company's ability to obtain or maintain patent or other
proprietary intellectual property protection; competition in general;
government, industry and general public pricing pressures; the impact that the
foregoing factors could have on the values attributed to the Company's assets
and liabilities as recorded in its consolidated balance sheet, and other risks
and factors referred to in Sigma-Aldrich's current Form 10-K on file with the
US Securities and Exchange Commission. Should one or more of these risks or
uncertainties materialize, or should underlying assumptions prove incorrect,
actual results may vary materially from those anticipated, believed, estimated
or expected. Sigma-Aldrich is providing the information in this press release
as of this date and does not undertake any obligation to update any
forward-looking statements contained in this press release as a result of new
information, future events or otherwise.

About Sigma-Aldrich: Sigma-Aldrich is a leading Life Science and High
Technology company whose biochemical, organic chemical products, kits and
services are used in scientific research, including genomic and proteomic
research, biotechnology, pharmaceutical development, the diagnosis of disease
and as key components in pharmaceutical, diagnostics and high technology SAFC
manufacturing. Sigma-Aldrich customers include more than 1.3 million
scientists and technologists in life science companies, university and
government institutions, hospitals and industry. The Company operates in 38
countries and has nearly 9,000 employees whose objective is to provide
excellent service worldwide. Sigma-Aldrich is committed to accelerating
customer success through innovation and leadership in Life Science and High
Technology. For more information about Sigma-Aldrich, please visit its website

About SAFC: SAFC, the custom manufacturing and services business unit of
Sigma-Aldrich Corporation, is recognized as a top 10 global specialty
chemicals and biologics supplier. As a trusted manufacturer for the life
science and high technology industries, SAFC works closely with customers to
resolve development challenges and accelerate the product pipeline utilizing
its global "Centers of Excellence" and dedicated manufacturing facilities. Its
rich portfolio includes high-purity inorganic materials for high technology
applications, critical raw materials and extensive biologics safety testing
services for biopharmaceutical manufacturing, and complex, high-potent APIs
and key intermediates for pharmaceutical manufacturing. For more information,

©2013 Sigma-Aldrich Co. LLC. All rights reserved. BioReliance and SAFC are
trademarks of Sigma-Aldrich Co. LLC or its Affiliates, registered in the US
and other countries.

SOURCE Sigma-Aldrich Corporation

Contact: Kristi Fortschneider, Marketing Communications Coordinator, SAFC, +
(314) 286-8331 x2407, or media, Beth Willers, Impress Labs, + (503) 928-7828,
Press spacebar to pause and continue. Press esc to stop.